These findings indicate that an obvious deficiency in the utility of serum anti-HOXA7 AAbs as a diagnostic biomarker is its extremely poor sensitivity for detecting poorly differentiated ovarian carcinomas [15]. The gene discussed is HOXA7; the disease is ovarian carcinoma.